EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 243 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended... February 18, 2025 Why People With Cancer Need to Be Taking Care of Their... August 27, 2020 UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation March 8, 2019 ESMO Welcomes European Parliament Resolution Marking World Cancer Day February 11, 2026 Load more HOT NEWS Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer A Better Biomarker for Cancer Immunotherapy? Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active...
